Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade

BACKGROUND: New molecular targets are needed for women with triple-negative breast cancer (TNBC). This pre-clinical study investigated the combination of the EGFR inhibitor gefitinib with the sphingosine kinase (SphK) inhibitor FTY720 (Fingolimod), aiming to block tumorigenic signaling downstream of...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Janet L., Julovi, Sohel M., Lin, Mike Z., de Silva, Hasanthi C., Boyle, Frances M., Baxter, Robert C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5545026/
https://www.ncbi.nlm.nih.gov/pubmed/28778177
http://dx.doi.org/10.1186/s13058-017-0882-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5545026/
https://www.ncbi.nlm.nih.gov/pubmed/28778177
http://dx.doi.org/10.1186/s13058-017-0882-x

Ejemplares similares